These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 36476380)

  • 41. Unraveling the genetic evolution of SARS-CoV-2 Recombinants using mutational dynamics across the different lineages.
    Ravi V; Shamim U; Khan MA; Swaminathan A; Mishra P; Singh R; Bharali P; Chauhan NS; Pandey R
    Front Med (Lausanne); 2023; 10():1294699. PubMed ID: 38288302
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
    Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
    Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography.
    Rössler A; Netzl A; Knabl L; Bante D; Wilks SH; Borena W; von Laer D; Smith DJ; Kimpel J
    Nat Commun; 2023 Aug; 14(1):5224. PubMed ID: 37633965
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.
    Cele S; Gazy I; Jackson L; Hwa SH; Tegally H; Lustig G; Giandhari J; Pillay S; Wilkinson E; Naidoo Y; Karim F; Ganga Y; Khan K; Bernstein M; Balazs AB; Gosnell BI; Hanekom W; Moosa MS; ; ; Lessells RJ; de Oliveira T; Sigal A
    Nature; 2021 May; 593(7857):142-146. PubMed ID: 33780970
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
    Collier DA; De Marco A; Ferreira IATM; Meng B; Datir RP; Walls AC; Kemp SA; Bassi J; Pinto D; Silacci-Fregni C; Bianchi S; Tortorici MA; Bowen J; Culap K; Jaconi S; Cameroni E; Snell G; Pizzuto MS; Pellanda AF; Garzoni C; Riva A; ; Elmer A; Kingston N; Graves B; McCoy LE; Smith KGC; Bradley JR; Temperton N; Ceron-Gutierrez L; Barcenas-Morales G; ; Harvey W; Virgin HW; Lanzavecchia A; Piccoli L; Doffinger R; Wills M; Veesler D; Corti D; Gupta RK
    Nature; 2021 May; 593(7857):136-141. PubMed ID: 33706364
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combined mutations in nonstructural protein 14, envelope, and membrane proteins mitigate the neuropathogenicity of SARS-CoV-2 Omicron BA.1 in K18-hACE2 mice.
    Sangare K; Liu S; Selvaraj P; Stauft CB; Starost MF; Wang TT
    mSphere; 2024 Dec; ():e0072624. PubMed ID: 39660912
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines.
    Bartsch YC; Tong X; Kang J; Avendaño MJ; Serrano EF; García-Salum T; Pardo-Roa C; Riquelme A; Cai Y; Renzi I; Stewart-Jones G; Chen B; Medina RA; Alter G
    Sci Transl Med; 2022 Apr; 14(642):eabn9243. PubMed ID: 35289637
    [TBL] [Abstract][Full Text] [Related]  

  • 48. C→U transition biases in SARS-CoV-2: still rampant 4 years from the start of the COVID-19 pandemic.
    Simmonds P
    mBio; 2024 Dec; 15(12):e0249324. PubMed ID: 39475243
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5.
    Duan M; Duan H; An Y; Zheng T; Wan S; Wang H; Zhao X; Dai L; Xu K; Gao GF
    Emerg Microbes Infect; 2023 Dec; 12(1):e2179357. PubMed ID: 36803449
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Brussonol and komaroviquinone as inhibitors of the SARS-CoV-2 Omicron BA.2 variant spike protein: A molecular docking, molecular dynamics, and quantum biochemistry approach.
    Santos SJM; Valentini A
    J Mol Graph Model; 2024 Nov; 135():108914. PubMed ID: 39637552
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nationwide seroprevalence of SARS-CoV-2 Delta variant and five Omicron sublineages in companion cats and dogs in the USA: insights into their role in COVID-19 epidemiology.
    Barua S; Iduu NV; Murillo DFB; Tarannum A; Dimino H; Barua S; Shu Y; Johnson C; Miller MR; Chenoweth K; Christopherson P; Huber L; Wood T; Turner K; Wang C
    Emerg Microbes Infect; 2025 Dec; 14(1):2437246. PubMed ID: 39635731
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice.
    Zhu J; Wang Z; Li Y; Zhang Z; Ren S; Wang J; Xie S; Liao Z; Song B; Wu W; Yan F; Peng C
    J Virol; 2024 Jul; 98(7):e0052124. PubMed ID: 38874361
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A chimeric adenovirus-vectored vaccine based on Beta spike and Delta RBD confers a broad-spectrum neutralization against Omicron-included SARS-CoV-2 variants.
    Hong W; Lei H; Peng D; Huang Y; He C; Yang J; Zhou Y; Liu J; Pan X; Que H; Alu A; Chen L; Ai J; Qin F; Wang B; Ao D; Zeng Z; Hao Y; Zhang Y; Huang X; Ye C; Fu M; He X; Bi Z; Han X; Luo M; Hu H; Cheng W; Dong H; Lei J; Chen L; Zhou X; Wang W; Lu G; Shen G; Yang L; Yang J; Li J; Wang Z; Song X; Sun Q; Lu S; Wang Y; Cheng P; Wei X
    MedComm (2020); 2024 May; 5(5):e539. PubMed ID: 38680520
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Identification of highly conserved surface-exposed peptides of spike protein for multiepitope vaccine design against emerging omicron variants: An immunoinformatic approach.
    Sultan Khan M; Shakya M; Kumar Verma C; Mukherjee R
    Hum Immunol; 2024 Nov; 85(6):111117. PubMed ID: 39276411
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhanced immunity against SARS-CoV-2 in returning Chinese individuals.
    Yuan R; Chen H; Yi L; Li X; Hu X; Li X; Zhang H; Zhou P; Liang C; Lin H; Zeng L; Zhuang X; Ruan Q; Chen Y; Deng Y; Liu Z; Lu J; Xiao J; Chen L; Xiao X; Li J; Li B; Li Y; He J; Sun J
    Hum Vaccin Immunother; 2024 Dec; 20(1):2300208. PubMed ID: 38191194
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of a SARS-CoV-2 mRNA booster immunization containing additional antigens to a spike-based mRNA vaccine against Omicron BA.5 infection in hACE2 mice.
    Hurst JR; Naghibosadat M; Budowski P; Liu J; Samaan P; Budiman F; Kurtesi A; Qi F; Menon H; Krishnan R; Abioye J; Gingras AC; Ostrowski M; Orozco NM; Kozak RA
    PLoS One; 2024; 19(12):e0314061. PubMed ID: 39625929
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study.
    van Gils MJ; Lavell A; van der Straten K; Appelman B; Bontjer I; Poniman M; Burger JA; Oomen M; Bouhuijs JH; van Vught LA; Slim MA; Schinkel M; Wynberg E; van Willigen HDG; Grobben M; Tejjani K; van Rijswijk J; Snitselaar JL; Caniels TG; ; Vlaar APJ; Prins M; de Jong MD; de Bree GJ; Sikkens JJ; Bomers MK; Sanders RW
    PLoS Med; 2022 May; 19(5):e1003991. PubMed ID: 35580156
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The neutralizing breadth of antibodies targeting diverse conserved epitopes between SARS-CoV and SARS-CoV-2.
    Xiong H; Sun H; Wang S; Yuan L; Liu L; Zhu Y; Zhang J; Huang Y; Qi R; Jiang Y; Ma J; Zhou M; Ma Y; Fu R; Yan S; Yue M; Wu Y; Wei M; Wang Y; Li T; Wang Y; Zheng Z; Yu H; Cheng T; Li S; Yuan Q; Zhang J; Guan Y; Zheng Q; Zhang T; Xia N
    Proc Natl Acad Sci U S A; 2022 Aug; 119(34):e2204256119. PubMed ID: 35972965
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A substitution at the cytoplasmic tail of the spike protein enhances SARS-CoV-2 infectivity and immunogenicity.
    Li Y; Zhang X; Tai W; Zhuang X; Shi H; Liao S; Yu X; Mei R; Chen X; Huang Y; Liu Y; Liu J; Liu Y; Zhu Y; Wang P; Tian M; Yu G; Li L; Cheng G
    EBioMedicine; 2024 Dec; 110():105437. PubMed ID: 39531918
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Profiling serum immunodominance following SARS-CoV-2 primary and breakthrough infection reveals distinct variant-specific epitope usage and immune imprinting.
    Seow J; Jefferson GCE; Keegan MD; Yau Y; Snell LB; Doores KJ
    PLoS Pathog; 2024 Nov; 20(11):e1012724. PubMed ID: 39556615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.